Zanidatamab
JZP598-303
Phase 3 small_molecule active
Quick answer
Zanidatamab for Metastatic HER2-positive Breast Cancer is a Phase 3 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- Metastatic HER2-positive Breast Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active